If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
=== Media preparation and washing units === The washing unit provides cleaning services for laboratory glassware and plasticware. It handles laundering of work clothing and decontamination of genetically modified organism (GMO) waste and hazardous laboratory waste. The media preparation unit prepares cultivation media and solutions for tissue culture. It produces bacteriological media and agar plates.
In March 2021, Columbia University professor Thomas J. Christensen wrote that the cold war between the US and China "is unlikely" in comparison to the original Cold War, citing China's prominence in the "global production chain" and absence of the authoritarianism vs. liberal democracy dynamic. Christensen further advised those concerned about the tensions between the two nations to research China's role in the global economy and its "foreign policy toward international conflicts and civil wars" between liberal and authoritarian forces. In September 2021, former Portuguese defence and foreign minister Paulo Portas described the announcement of the AUKUS security pact and the ensuing unprecedented diplomatic crisis between the signatories (Australia, the United Kingdom, and the United States) and France (which has several territories in the Indo-Pacific) as a possible formal starting point of a new Cold War. On 7 November 2021, President Biden's national security adviser Jake Sullivan stated that the US does not pursue system change in China anymore, marking a clear break from the China policy pursued by previous US administrations. Sullivan said that the US is not seeking a new Cold War with China, but is looking for a system of peaceful coexistence. In November 2021, Hal Brands and Yale professor John Lewis Gaddis wrote in Foreign Affairs that while it was no longer debatable that the United States and China has been entering into their "own new cold war", it was not clear that the world has also been following suit and entering into a new cold war.
==== Emergency Flying Rations (EFR) Mark 4 ==== The Mark 4 EFR is designed for crews of fast jets. It consists of a flat tin it contains 100 g of fruit flavoured sweets, (9 to be eaten each day) 2 spring handles and a plastic bag. The container can be used for boiling water and hot drinks can be made by dissolving the sweets in hot water. The Mark 4 EFR is built into ejector seats.
== Views == In his autobiography, Scottish commentator Bill McLaren wrote in 1991: "It has been a disgrace that a World Rugby Union power has been eliminated from world competition for all those years, even allowing for their country's unacceptable racist policy." Ian Robertson documented how the Springboks' position slowly deteriorated over the decades, but suggested that the fault lay outside the rugby fraternity:
Sources: en.wikipedia.org
Though the push-pull technique was invented as a strategy to control stem-boring moths, such as Chilo partellus, through the manipulation of volatile host-finding cues, it was later discovered that allelopathic substances exuded by the roots of Desmodium spp. also contribute to the suppression of the damaging parasitic weed, Striga.
In-space manufacturing uses processes such as additive manufacturing (printing a 3D object in successive layers), subtractive manufacturing (making 3D objects by successively removing material from a solid), hybrid manufacturing (usually combining additive manufacturing and subtractive manufacturing) and welding (joining pieces of material by melting or plasticizing along a joint line). In-space manufacturing removes spacecraft design limitations due to launch parameters (mass, vibration, structural load, etc.) and volume limitations imposed by payload size. It allows for recycling of launched materials, utilization space-mined resources and on-demand spare parts production, which enables on-site repair of critical parts (increasing reliability and redundancy) and infrastructure development. It takes advantage of unique space features such as microgravity, ultra-vacuum and containerless processing, which are difficult to do on Earth.
After the war, the party was refounded, but it was confronted with the emergence of the Christian Democratic Union (CDU), a new party formed as a Christian party comprising both Catholics and Protestants. As many former Centre party politicians, such as Konrad Adenauer, were founding members or joined the CDU, and Cardinal Josef Frings of Cologne endorsed the new party, the party lost its position as the party of the Catholic population. For some time, however, the party managed to hold on to regional strongholds in North Rhine-Westphalia. In 1945, its Rudolf Amelunxen had been the new state's first Minister-President, and it participated in the state government until 1958, when it left the state parliament. Until 1959, the Centre was also represented in the state parliament of Lower Saxony. On the national level, in the elections of 1949, it won ten seats in the first Bundestag. However, in 1953, the party (with the aid from the regional CDU) only retained three seats. In 1957, largely due to the massive CDU landslide that year, the party dropped out of the Bundestag completely and it did not return until 2022. This demise is at least partly because of Helene Wessel. In 1949, she was one of the Centre's representatives in the Bundestag and also was elected chairwoman of the party, the first woman ever to lead a German party. In 1951, she vocally opposed Adenauer's policy of West German rearmament and joined forces with the CDU's Gustav Heinemann, the former Minister of the Interior.
== Identification == S. haemolyticus can be identified on the species level using a variety of manual and automated methods. The most frequently employed are: the reference method (based on growth tests), API ID 32 Staph (bioMe´rieux), Staph-Zym (Rosco), UZA (a rapid 4-h method), and polymerase chain reaction and electrophoretic analysis of the 16S rRNA, hsp60, or sodA gene sequence. Preference towards a particular method usually depends on convenience, economics, and required specificity (some species have identical 16S rRNA). The most closely related species of S. haemolyticus is Staphylococcus borealis.
In any case, the serotonin 5-HT2A receptor antagonist ketanserin blocked not only the psychoactive but also the physical side effects of mescaline including nausea and vomiting, suggesting that these effects may be mediated by serotonin 5-HT2A receptor activation. Mescaline has been found to increase oxytocin levels in humans and to a greater extent than LSD or psilocybin at equivalent doses. There is no evidence of acute tolerance with mescaline. However, tolerance to mescaline builds with repeated use, lasting for a few days. The drug causes cross-tolerance with other psychedelics like LSD and psilocybin. The cryo-EM structures of the serotonin 5-HT2A receptor with mescaline, as well as with various other psychedelics and serotonin 5-HT2A receptor agonists, have been solved and published by Bryan L. Roth and colleagues. Mescaline has been found to bind to tubulin and act as a highly potent mitotic inhibitor similarly to its cyclized derivatives colchicine and demecolcine. Aside from the identification of this action however, it does not appear to have been further studied.
Sources: en.wikipedia.org
=== Gas chromatography with mass spectrometry (GC-MS) === Gas chromatography with mass spectrometry (GC-MS) is considered the gold standard for VOC analysis to identify specific compounds. The chromatography separates the sample mixture in a gaseous state by forcing them through a column using a carrier gas, and the mass spectrometer identifies the compound. The limitation of this method is the requirement of expensive specialized equipment and highly trained personnel. VOC analysis is seen in asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), chronic obstructive sleep apnea (OSA), inflammatory bowel disease, cancer, infections, and among others.
Meloxicam use can result in gastrointestinal toxicity and bleeding, headaches, rash, and very dark or black stool (a sign of intestinal bleeding). It has fewer gastrointestinal side effects than diclofenac, piroxicam, naproxen, and perhaps all other NSAIDs which are not COX-2 selective. In October 2020, the US Food and Drug Administration (FDA) required the prescribing information to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid. They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.
27 October – Former Health Secretary Alex Neil calls for an urgent review of the use of WhatsApp by government following revelations that National Clinical Director Jason Leitch deleted messages on a daily basis during the pandemic; he also says that many government ministers did not understand the rules for using the app. 28 October – Ash Regan, who stood as a candidate in the 2023 SNP leadership election, defects to the Alba Party after becoming disillusioned with what she describes as the SNP's "wavering commitment" to Scottish independence. 29 October – First Minister Humza Yousaf says he has made contact with his in-laws trapped in Gaza for the first time since a communications blackout two days earlier. The Sunday Mail reports that WhatsApp messages relating to the COVID-19 pandemic sent by First Minister of Scotland, Nicola Sturgeon, were manually deleted from her phone. 30 October – First Minister Humza Yousaf says that allegations he deleted WhatsApp messages relating to the COVID-19 pandemic are "certainly not true". 31 October – Scotland's Deputy First Minister, Shona Robison, confirms that Scottish Government will hand 14,000 electronic messages relating to the pandemic to the UK COVID-19 Inquiry.
Plays a central role in signal transmission speed and integration. White matter hyperintensities Lesions seen on MRI as bright spots in the brain's white matter, often associated with aging, vascular disease, and cognitive decline. Wilson's disease A rare genetic disorder involving impaired copper metabolism that leads to copper buildup in the brain, liver, and other tissues. Neurological symptoms include tremors, dystonia, and psychiatric changes. Wolfram syndrome A rare genetic disorder involving diabetes insipidus, diabetes mellitus, optic atrophy, and deafness (DIDMOAD). Associated with neurodegeneration and mitochondrial dysfunction. Working memory A form of short-term memory that allows temporary storage and manipulation of information necessary for tasks like reasoning and comprehension. Often localized to the dorsolateral prefrontal cortex. Wrist drop A neurological condition caused by radial nerve damage, resulting in an inability to extend the wrist and fingers. Often associated with nerve compression or trauma.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.